MEDI9197 + durvalumab

MEDI9197 + durvalumab is a combination regimen investigated for advanced solid tumors, comprising intratumoral MEDI9197, a toll-like receptor 7 and 8 (TLR7/8) agonist, with intravenous durvalumab, a monoclonal antibody checkpoint inhibitor targeting programmed cell death ligand-1 (PD-L1)[1][2][3][4]. MEDI9197 stimulates local and systemic antitumor immune responses via TLR7/8 activation, resulting in increased CD8+ T cells, PD-L1+ cells, induction of type 1 and 2 interferons, and a T helper 1 response. Durvalumab blocks PD-L1, preventing T cell inhibition and facilitating immune-mediated tumor cell killing. Developed to be administered by intratumoral injection for MEDI9197 and intravenous infusion for durvalumab, the combination was tested in a phase 1 trial for safety, pharmacodynamics, and anti-tumor activity. No objective responses were observed, but immune activation was demonstrated, and disease stabilization occurred in some participants[1][2][3][4].

Other names

MEDI9197MEDI-9197MEDI 9197durvalumab